Download Files:
Icenticaftor
$452 – $5,500
Products Details
Product Description
– Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research[1].
Web ID
– HY-109177
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C12H13F6N3O3
References
– [1]Darren Le Grand, et al. Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. J Med Chem. 2021 Jun 10;64(11):7241-7260.|[2]Steven M Rowe, et al. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial. Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409.
CAS Number
– 1334546-77-8
Molecular Weight
– 361.24
Compound Purity
– 99.87
SMILES
– O=C(C1=NC(OC)=C(C(F)(F)F)C=C1N)NC[C@](C)(O)C(F)(F)F
Clinical Information
– Phase 2
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 150 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– CFTR
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
